Newsletters and Deep Dive digital magazine
As a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new care infrastructure.
LONDON, UNITED KINGDOM, April 19th 2017:
SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
An inside guide to unlocking clinical research in the UK